【SUNZEN 0148 交流专区】宏诚生科

icy97

Type	Announcement
Subject	OTHERS
Description	- REVALUATION OF NON-CURRENT ASSETS
In accordance with Rule 9.19(46) of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors (“Board”) of Sunzen Biotech Berhad (“Sunzen” or “Company”) wishes to inform that the Board of Sunzen had on 28 August 2024 approved the valuation report for the properties held by its subsidiaries and the incorporation of the revaluation surplus of RM9,868,610 into the Group’s unaudited financial results on consolidated results for the financial quarter ended 30 June 2024. Please refer to the attachment for the details of the announcement. This announcement is dated 29 August 2024.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3479222

Attachments Revaluation of Non-Current Assets.pdf

icy97

SUNZEN BIOTECH BERHAD

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-23092024-00001
Subject	Article Entitled: "Sunzen Biotech aims to sell assets"
Description	SUNZEN BIOTECH BERHAD ("SUNZEN" OR "THE COMPANY)Article Entitled: "Sunzen Biotech aims to sell assets"
Query Letter Contents	We refer to the above media article appearing in NewStraitsTimes dated 23 September 2024, a copy of which is enclosed for your reference. In particular, we would like to draw your attention to the underlined sentence which is reproduced as follows :- "Sunzen Biotech Bhd plans to divest its land and factory in Kota Kemuning, Shah Alam, Selangor, with a market value estimated between RM16million and RM18million." In accordance with Bursa Securities' Corporate Disclosure Policy, kindly furnish Bursa Securities with an announcement for public release confirming or denying the above reported article in particular the underlined sentences after due and diligent enquiry with all the directors, major shareholders and all such other person reasonably familiar with the matters about which the disclosure is to made in this respect. In the event you deny the above reported sentences or any other part of the article, you are required to set forth facts sufficient to support the same.
Clarification on the Article Published in The New Straits Times on 23 September 2024With reference to the article titled "Sunzen Biotech Aims to Sell Assets" published in The New Straits Times on 23 September 2024 (the "Article"), specifically regarding the statement:“Sunzen Biotech Bhd plans to divest its land and factory in Kota Kemuning, Shah Alam, Selangor, with a market value estimated between RM16 million and RM18 million.”The Board of Directors of Sunzen Biotech Berhad ("the Board") has conducted a thorough inquiry involving all directors, major shareholders, and management regarding recent media inquiries dated 20 September 2024. The Board wish to clarify that while the management referenced the matter during these press inquiries, this was in the context of an initial study and planning phase related to the cessation of our animal health division, which the Company has previously announced on 8 April 2024.It is important to note that the discussions are still exploratory and have not yet been presented to the Board for further consideration. Additionally, the valuation amount mentioned in the article is based on a recent valuation conducted by the Sunzen Group’s properties, which was announced on 29 August 2024.Once the feasibility study is finalised and the Board’s approval is obtained, the Company will make the necessary announcements to Bursa Malaysia Securities Berhad.This announcement is dated 24 September 2024.

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	SUNZEN BIOTECH BERHAD ("THE COMPANY" OR "SUNZEN") -        ACQUISITION OF SHARES IN EYE NATION MEDICAL SDN. BHD.
Further to the Company’s announcement on 6 May 2024, the Board of Directors of Sunzen (“Board”) wishes to announce that the Company, had on 1 October 2024 entered into a Share Sale Agreement (“SSA”) with Mr. Lee Peng Hwa (“Lee”) and Madam Lay Lee Chin (“Lay”) (collectively referred to as “the Vendors”), for the acquisition of seventy thousand (70,000) ordinary shares (“Sale Shares”), representing seventy percent (70%) of the equity interest of Eye Nation Medical Sdn. Bhd. [Registration No. 200301031140 (633561-V)] (“ENMSB”) for a total cash consideration of Ringgit Malaysia Six Million Three Hundred and Seventy Thousand (RM6,370,000.00) only (“Purchase Price”) (“the Acquisition”) in accordance with the terms and conditions of the SSA. Please refer to the attachment for details of the announcement. This announcement is dated 1 October 2024.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3488216

Attachments Sunzen_Ann_Acq of Shares_Eye Nation_FINAL.pdf

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	SUNZEN GROUP BERHAD ("THE COMPANY" OR "SUNZEN") (FORMERLY KNOWN AS SUNZEN BIOTECH BERHAD)SALE AND PURCHASE OF SHARES AGREEMENT WITH PURE NUTRITIONAL PRODUCTS SDN. BHD. IN RESPECT OF - (1)        DISPOSAL OF 2,000,000 ORDINARY SHARES IN SUNZEN CORPORATION SDN. BHD.(2)        DISPOSAL OF 500,000 ORDINARY SHARES IN SUNZEN LIFESCIENCES SDN. BHD.(“DISPOSAL OF SHARES”)
The Company had on 18 February 2025 entered into a Sale and Purchase of Shares Agreement (“Agreement”) with Pure Nutritional Products Sdn. Bhd. [Registration No. 199801003406 (45932-H)] (“Pure Nutritional” or “Purchaser”) for disposal of 100% of the equity interest in its wholly-owned subsidiaries namely Sunzen Corporation Sdn. Bhd. [Registration No. 199801014339 (470468-W)] (“SCSB”) and Sunzen Lifesciences Sdn. Bhd. [Registration No. 200701000077 (758075-D)] (“SLSB”) (collectively known as “Target Companies”), which operates in the animal health businesses, for a total cash consideration of Ringgit Malaysia Seventeen Million Three Hundred Thousand (RM17,300,000.00) only (“Consideration”) (“Disposal of Shares”). Please refer to the attachement for details of the announcement. This announcement is dated 18 February 2025.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3524231

Attachments Sunzen_SPA_Pure Nutritional Products.pdf

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	SUNZEN GROUP BERHAD ("THE COMPANY" OR "SUNZEN") (FORMERLY KNOWN AS SUNZEN BIOTECH BERHAD)SALE AND PURCHASE OF SHARES AGREEMENT WITH PURE NUTRITIONAL PRODUCTS SDN. BHD. IN RESPECT OF - (1)DISPOSAL OF 2,000,000 ORDINARY SHARES IN SUNZEN CORPORATION SDN. BHD.(2)DISPOSAL OF 500,000 ORDINARY SHARES IN SUNZEN LIFESCIENCES SDN. BHD.("DISPOSAL OF SHARES")
Unless otherwise defined herein, all terms and acronyms used herein shall be the same as those defined in the Company’s announcement dated 18 February 2025. Further to Sunzen’s announcement dated 18 February 2025 in relation to the Sale and Purchase of Shares Agreement with Pure Nutritional Products Sdn. Bhd. in respect of the Disposal of Shares. The Board of Directors of Sunzen wishes to announce the following additional information:- 1. Particular of any liabilities, including contingent liabilities, in relation to the Proposed Disposal which remain with Sunzen, together with the details and justification for such arrangements. Sunzen remain responsible for contingent liability under SCSB arising from the legal case that initiated against SCSB by the claimant. However, SCSB should not be held liable for occupier liability and vicarious liability as claimed and has applied for striking out for the case, of which is pending the decision by the Court. 2. Quantify the liability of the Target Companies which will remain with Sunzen. In the event the Court decides otherwise, SCSB would be liable for a claim of RM6,500.00 as well as the general damages which shall be decided and assessed by the Court accordingly. The general damages could not be quantified at the current state. However, based on the Company's legal advisor and internal assessment, the general damages are unlikely to have any material impact on Sunzen, if the Court ruled in favour of the claimant. 3. Any guarantee given to the Target Companies. There was no guarantee given by Sunzen to the Target Companies. 4. Directors’ and substantial shareholders’ shareholding of the Purchaser. The Directors of Pure Nutritional and their respective shareholding in Pure Nutritional are as follows:- Name Shareholding Direct Indirect Diong Sing Peng 1 (0.01%) Nil Diong Siew Gi 15,001 (99.99%) Nil Diong Swee Hoon Nil Nil

Pure Nutritional is a private limited company under the Companies Act 2016. Substantial shareholder is not applicable to Pure Nutritional in accordance with Section 134 of the Companies Act 2016.

This announcement is dated 20 February 2025.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2024

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2024	31 Dec 2023	31 Dec 2024	31 Dec 2023
		MYR'000	MYR'000	MYR'000	MYR'000

1	Revenue	27,346	0	50,310	0
2	Profit/(loss) before tax	2,893	0	3,753	0
3	Profit/(loss) for the period	2,034	0	2,285	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,942	0	2,424	0
5	Basic earnings/(loss) per share (Subunit)	0.27	0.00	0.33	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent	0.1900		0.2000

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2025

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2025	31 Mar 2024	31 Mar 2025	31 Mar 2024
		MYR'000	MYR'000	MYR'000	MYR'000

1	Revenue	15,687	0	65,997	0
2	Profit/(loss) before tax	1,924	0	5,677	0
3	Profit/(loss) for the period	1,271	0	3,556	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,187	0	3,611	0
5	Basic earnings/(loss) per share (Subunit)	0.16	0.00	0.50	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent	0.1900		0.2000